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The  role  of complement in  blood  coagulation is  far  from clear.  A  clotting 
abnormality was reported  (1,  2)  in rabbits deficient in the sixth component of 
complement (C6),  however, no clotting abnormality was detected in a  human 
patient deficient in the same component (3). When platelets were incubated in 
fresh human serum, C3 and C5-C9 complexes were demonstrated on the platelet 
membrane  as  well  as  C5-C9  complexes  in  the  fluid  phase  of the  reaction 
mixture (4). Further, retraction and lysis of thrombin-induced blood clots were 
inhibited by antiserum to C3 and C4 (5). We have previously reported (6) that 
complement-dependent ultrastructural lesions were visualized on the platelet 
surface subsequent to their incubation with thrombin and complement. 
In the present  study, thrombin-mediated specific uptake of C3  and C5 was 
demonstrated by uptake of radiolabeled components and was visualized ultra- 
structurally utilizing ferritin-conjugated monospecific antiserum to each of the 
two components. To develop these studies further, the role of complement in 
thrombin-induced platelet function was investigated. It was found that whereas 
complement was not essential for thrombin-mediated platelet aggregation and 
release of serotonin, these two activities were much enhanced in the presence of 
complement. When the nature of the complement interaction was determined, 
it was found that components C3, C5, C6, C7, C8, and C9 were essential for this 
enhanced  reactivity;  however,  these  six  components  in  the  absence  of any 
previously described C3 convertase were the only components of the complement 
system that were required. Evidence is presented identifying a new pathway of 
activation of complement-one that is dependent on the presence of thrombin 
and the platelet membrane and enters the known complement sequence at the 
C3 stage. 
Materials and Methods 
Preparation  of Washed Platelets.  A  suspension of human  platelets was prepared using the 
Ardlie buffer system as previously described 17~ with the following modification. Because the pH 
of the Ardlie buffers was found rapidly to increase, the sodium bicarbonate in each buffer was 
replaced by Tris (hydroxymethyll amino methane ITrizma basel at the same molarity, namely, 
0.012  M.  Under these conditions, the pH of the buffers remained constant at pH 7.3 throughout 
the experiment. 
Preparation  of Aluminum  Itydroxide-Absorbed  Serum.  Fresh human  serum  was  absorbed 
with aluminum hydroxide as previously described t6~ under conditions that were shown to remove 
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prothrombin but not to inactivate complement. Serum was considered to be prothrombin free if, 
after incubation with fibrinogen (1.5 mg/ml) for 48 h, no clot was formed. Assays were performed 
to  measure  activity  of whole  component  and  components  of both the  classic  and  alternative 
mechanism as previously described (6/. 
Preparation of Complement Components and Reagents.  C3(8), C4(9), C5(8), C6, C7(10), C8(111, 
and  C9(12)  were  prepared  by  methods  described  earlier.  In  addition,  for  some  experiments 
purified  complement  components  prepared  by  Cordis  Laboratories,  Inc.  IMiami,  Fla. t  were 
utilized. C3a and C5a were produced by trypsin treatment of the parent molecule and molecular 
sieve  chromatography  (13,  141. Aluminum  hydroxide  (Al[OH]3)-absorbed  serum  was  further 
treated with potassium thiocyanate (KSCN) 1 under conditions known to inactivate C3,  C4,  and 
C5(15). In reconstitution experiments, 25 t~g C3, 17 ttg C4, and 3 tLg C5 were added either singly 
or in combination to  10 ill of Al(OH)3-absorbed KSCN-treated  serum.  A reagent that contained 
C3, C5, C6, and C7 and not C8 and C9 was also prepared (11). 
Human  serum  totally deficient in  C2  was kindly supplied by Doctors  Kunkel  and S.  M.  Fu 
(The Rockefeller University, New York). Factor B-depleted serum was prepared by heating fresh 
human serum at 50°C for 30 min (16}. A serum reagent lacking C2 and Factor B was prepared by 
heating the C2-deficient serum  at  50°C  for 30  rain.  Each  serum  was absorbed with aluminum 
hydroxide  as  described  above.  In  the  case of the  heated  sera,  the  absorption with  aluminum 
hydroxide was performed before the heating step. 
Monospecific antisera to C2,  C3,  C5,  C8,  and C9 were prepared in rabbits by injection of the 
purified  protein  into the  popliteal  lymph  nodes  followed  a  month  later  by  an  intramuscular 
injection of the same protein  (17/.  The antisera were extensively tested immunochemically for 
specificity  and  if they  were  found  not  to  be  monospecific,  they  were  appropriately  absorbed. 
Monospecific  anti-human  serum  albumin  and  anti-Factor  B  were  purchased  from  Behring 
Diagnostics, Inc. (Woodbury, N.Y.). 
Platelet  Aggregation.  Assays  for  platelet  aggregation  were  performed  in  a  Payton  dual 
channel aggregometer  using a  Riken  Denshi recorder  (Payton Associates Inc.,  Buffalo,  N.Y.L 
Platelets were suspended at 200,000/t~l  in Ardlie II buffer in which bicarbonate had been replaced 
with Tris (see abovel. All reagents added to the platelets were dialyzed before u~e vs. cacodylate 
buffer pH 7.4, a buffer shown to be optimal for aggregation of washed platelets (18).  Highly puri- 
fied human thrombin (2.05  U/t~gl was prepared and kindly supplied by Dr.  John Fenton, New 
York  State  Department of Health,  Albany,  N.Y.  0.1  U  in  10  ~l  was  added  to  0.3  ml  washed 
platelets. 
Release of 14C-Serotonin.  Platelets suspended  in plasma were labeled with ~C-serotonin by 
the method of Valdorf-Hansen and Zucker (19}. The radiolabeled platelets were then washed in 
the usual way. For the experiment, 0.3 ml platelet suspension was utilized to which 10 t~l aliquots 
of  various  reagents  were  added.  Aggregation  was  recorded  for  5  min,  then  the  tube  was 
centrifuged and the supernate removed. ~4C was counted in both the supernate and the cell button 
in a  Packard  Liquid  Scintillation counter  (Packard Instrument Co.,  Inc.,  Downer's Grove,  Ill.l 
and percent release was calculated. 
Release  of Lactic  Dehydrogenase  ¢LDH).  LDH  release  was  determined  by  the  method  of 
Wroblewski and LaDue 120). 1 U was expressed as decrease in OD at 340 t~m of 0.001/min per ml. 
Release of LDH during incubation periods from 1 min to 2 h was determined. 
Ferritin  Conjugation  of Antisera.  Monospecific antisera to C3  and C5 were conjugated with 
ferritin by the method of Tawde  and Ram  (211. Free ferritin and unconjugated 7-globulin were 
separated from the conjugated 7-globulin by pevikon block electrophoresis (22). 
Preparation  of Platelets for Electron  Microscopy.  Complement was activated on the platelet 
surface by the methods described in detail below. After incubation with complement, the platelets 
were washed three times with saline.  The platelet button was then suspended in a  dilution of 
ferritin-conjugated antibody and incubated at 37°C for 30 rain. After this incubation the platelets 
were washed three times in saline, then divided into two aliquots. One aliquot was then washed 
three times in a  1/10  dilution of saline buffered to pH 6.5,  After the first wash step at this low 
ionic  strength,  the  platelets  were  frozen  and  thawed  twice  to  lyse  them,  and  the  unstained 
platelet membranes were viewed  in a  Philips 301 Electron Microscope  (see Fig.  1~.  The second 
I Abbreviations  used  in  this  paper:  DFP,  diisopropyl  fluorophosphate,  KSCN,  potassium 
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al,.'quot ofplatelets was embedded, sectioned, and stained in the usual way and then viewed under 
the electron microscope (see Fig. 2). 
Radiolabeling of Complement Components.  C3 and C5 were labeled with ~5I by the method of 
McConahey and Dixon (23). The specific activity of C3 was approximately 200,000 cpm/t~g; and of 
C5 was approximately 60,000 cpm/gg. 
Activation of Complement on the Platelet Surface.  The serum concentration of C3 was assumed 
to be 1.3 mg/ml and of C5 80 t~g/ml.  For each experiment either 25 ixl of ]~5I-C3 containing 20.5 tLg 
of protein or 25 t~l of 1~5I-C5 containing 5.25  ttg was added to 0.25  ml of undiluted human serum. 
Complement  was  activated  on  the  platelet  surface  by  (a~  the  classic  mechanism,  (b)  the 
alternative mechanism, and (c) by thrombin: 
~a)  Activation of complement by the classic mechanism: 0.5 ml of a platelet suspension at 1.5 
×  109/ml was incubated with 0.25 ml serum containing an isoantibody to a nonidentified platelet 
antigen and 0.25  ml of fresh serum containing either ~zSI-labeled C3 or C5.  After incubation at 
37°C for 90 min, the tubes were spun and the cell button was washed five times with saline before 
counting. 
(b)  Activation of complement by the alternative mechanism: 0.25 ml of the platelet suspension 
was mixed with 0.25  ml of inulin at  10 mg/ml. The mixture was centrifuged and the supernate 
was discarded. To the inulin-platelet mixture was added 0.25 ml serum containing either ~zsI-C3 
or ~:sI-C5. After incubation at 37°C for 90 min, the tubes were centrifuged and the cell button was 
washed five times with saline. 
I  c~  Activation of complement with thrombin: 0.5 ml of the platelet suspension was mixed with 
0.25  ml serum containing 0.25  U  of thrombin and ~5I-C3 or C5.  After incubation at 37°C for 90 
min, the tubes were centrifuged and the cell button was washed five times with saline. 
In  an  experiment to determine the role of the platelet in  the activation of complement by 
thrombin, a  similar method was used except that the platelets were replaced by either human 
erythrocytes at  5  x  10S/ml or  leukocytes  at  5  ×  107/ml. The  leukocyte  preparation  was  the 
supernate from dextran-sedimented defibrinated whole blood. 
In each of the above experiments the negative control for nonspecific uptake of radiolabeled 
complement component was supplied by a  similar reaction mixture containing 0.01 M EDTA. In 
each case this figure was subtracted from the total uptake to provide specific uptake. 
Inhibition  of Aggregation  and Release of Serotonin  by Monospecific  Antisera.  Monospecific 
antisera to C2,  C3,  C5,  C9,  Factor B,  and human serum albumin were utilized. 0.2  ml of each 
antiserum was applied to a O-triethylaminoethyl-cellulose column equilibrated with phosphate 
buffer pH 8.0 and 0.0175 M. The "y-globulin fraction was eluted with the same buffer. The fraction 
containing the peak of ~globulin was used in an unconcentrated form. 0.3 ml was incubated at 
37°C for 15  min with 20  gl of antibody. Subsequent to this incubation, the tube containing the 
antibody-platelet mixture was transferred to  the platelet aggregometer, and  10  ttl  samples of 
various complement components or reagents were added  (see Results~.  The anti-human serum 
albumin was used in each experiment as the negative control. 
Treatment of Thrombin  with Diisopropyl Fluorophosphate  cDFP~.  DFP at  a  final concentra- 
tion of 2 ~  10  :~ M was added to thrombin at 100 U/ml. The mixture was allowed to stand at 0°C for 
30 min then was dialyzed extensively vs. normal saline. 
Results 
Uptake of 1-'51-C3 and r'sI-C5 by Platelets.  As shown in Table I, activation of 
complement  on  the  platelet  surface  by  either  the  classic  or  the  alternative 
pathway  led  to  uptake  of  40-60,000  molecules  of  C3  per  cell  and  3-4,000 
molecules  of C5.  However,  incubation  of platelets  with  complement  in  the 
presence of thrombin led to a similar uptake of C5 but to a much reduced uptake 
of C3. 
Incubation of complement with erythrocytes or leukocytes in the presence of 
thrombin led to an uptake of C3 and C5 that was not distinguishable from the 
EDTA-containing control. 
Morphologic  Demonstration  of  Thrombin-Induced  Uptake  of  C3  and 1716  COMPLEMENT  AND  PLATELET  FUNCTION 
TABLE  [ 
Uptake of C3 at~d C5 by Platelets When Complemel~t is Activated 
by Three Different Mechanisms 
Number of molecules per platelet 
Activation of comple- 
ment induced by*  C3  C5 
Antibody  39,800  4,200 
Inulin  61,600  2,900 
Thrombin  4,400  3,600 
* For details of method of activation of complement, see text, 
C5.  Distribution of ferritin conjugated to anti-C3 or anti-C5 on the surface of 
the platelet membrane is shown in Fig.  1. When complement was activated by 
thrombin,  the amount of bound labeled anti-C3  was  minimal as compared to 
the uptake when complement was  activated by either the classic  (Fig.  1 c} or 
alternative mechanism (not shown). The platelet membranes from the throm- 
bin-mediated reaction demonstrated large areas totally devoid of ferritin, and 
the ferritin when present was  found to be localized in large clusters of 20-30 
molecules. The uptake and distribution of ferritin conjugated to anti-C5  I  Fig. 
1 b) were similar to that seen when complement was activated on the platelet 
surface by the antibody-mediated classic mechanism (Fig.  1 d).  Fig.  2 a  and b 
are stained sections of platelets reacted with thrombin and complement reacted 
with ferritin-conjugated anti-C3 (Fig. 2 a) or anti-C5 (Fig. 2 b). 
Mechanism of Activation of Complement by Thrombin.  We have previously 
reported  (6)  that  subsequent  to the  incubation  of platelets,  thrombin,  and  a 
source of complement, ultrastructural lesions can be visualized on the surface of 
the platelet. To elucidate the mechanism of activation of complement, platelets 
were incubated with thrombin in the presence of serum from a patient deficient 
in C2.  Ultrastructural lesions were still seen on the platelets,  indicating that 
this total blockage of the classic mechanism had not prevented formation of the 
lesions. A blockage of the alternate pathway was initiated by heating serum at 
50°C for 30 min to inactivate Factor B. Platelets incubated in heated serum in 
the presence of thrombin still exhibited ultrastructural lesions. 
The Effect of Aluminum Hydroxide-Absorbed Serum on  Thrombin-Induced 
Aggregation  of Washed Platelets.  Fig.  3 demonstrates aggregation of 0.3-ml 
platelets by 0.1 U of thrombin either in the presence (at or absence (b) of 10 ~tl 
of aluminum hydroxide-absorbed serum.  The Al(OH).~-absorbed serum  in the 
absence of thrombin induced no platelet aggregation. 
The  Effect  of Al(OH):~-Absorbed  Serum  on  Thrombin-Induced  Release  of 
Serotonin.  Release of 14C-serotonin from platelets induced by varying amounts 
of thrombin either in the presence or absence of aluminum hydroxide-absorbed 
serum is shown in Table II.  There was a  two- to fourfold increase in the  I~C- 
serotonin released by thrombin in the presence of the serum over that obtained 
with thrombin alone. This was most evident at the lower dose range ofthrombin 
(0.025 and 0.05 U). 
The Effect of AI(OH):I-A bsorbed Serum on Release of Lactic Dehydrogenase 
(LDH).  Under  the  conditions  utilized  in  the  present  study,  namely  0.1  U MARGARET  J.  POLLEY  AND  RALPH  NACHMAN  1717 
Fro.  1.  Preparation  of' platelet  membranes  reacted  with  ferritin-conjugated  antibody. 
Unstained.  × 110,000.  (a and b): Complement activated by thrombin.  (a) Anti-C3 conjugated 
with  ferritin;  (b)  anti-C5  conjugated  with  ferritin;  (c  and  d)  complement  activated  by 
antibody-mediated  classic  mechanism;  (c)  anti-C3  conjugated  with  ferritin;  /d)  anti-C5 
conjugated with ferritin. 
thrombin per 0.3-ml platelets, no LDH was liberated from platelets by thrombin 
either in the presence or absence of aluminum hydroxide-absorbed serum even 
after an incubation period of 2 h at 37°C. 
The  Effect  of KSCN  Treatment  of Al(OH)3-Absorbed  Serum.  Al(OH)3- 
absorbed serum when further treated with KSCN under conditions known to 
inactivate  C3,  C4,  and  C5  (15)  failed to  enhance significantly the  release of 
serotonin by thrombin (Fig. 4). However, addition of 25 t~g of highly purified C3 
and 3.1  t~g of C5 restored the enhancing ability of the serum. Addition of 17.6 
t~g of C4 had little or no effect. 1718  COMPLEMENT  AND  PLATELET  FUNCTION 
FIG.  2.  Platelets reacted with thrombin and complement; then ferritin-conjugated anti- 
body; sectioned and stained  ×  100,000.  Arrows  indicate clumps of ferritin molecules.  (a) 
Anti-C3 conjugated with ferritin; (b) anti-C5 conjugated with ferritin. 
Use of  Purified Complement Components in Platelet Aggregation  and Release 
Reactions.  Figs. 4 and 5 show the results of multiple experiments. The large 
standard deviations are the result of a  considerable variation in the degree of 
agglutination and  release  of serotonin  given  by  platelet  preparations  from 
different donors. Whether the difference is due to drugs, food, etc. in different 
donors was not determined. However, with a single batch of platelets on a given 
day, the trends were always reproducible. 
The sequence of addition of thrombin and purified complement components 
was  important  in  determining the  extent  of platelet  ~4C-serotonin  release. 
When  thrombin  was  added  before  C3-C9,  serotonin  release  was  enhanced 
compared  to  the  experiments  in  which  C3-C9  was  added  before  thrombin 
(Fig. 5).  In multiple experiments, the highest degree of serotonin release was 
obtained when C3, C5, C6, C7, C8, and C9 were added. However, some enhance- 
ment of release of serotonin was obtained when C3  alone was added or when 
C3 and C5 were added or when C3,  C5,  C6,  and C7 were added.  Some release 
enhancement was also noted in the presence of C8 and C9.  Despite the large 
standard deviation, the enhancement of serotonin release by C3-C7 was always 
less than that produced by C3-C9 with any single batch of platelets. 
As a result of these experiments, the question arose as to whether C8 and C9 
were  bound  to  the  platelet  surface  and  were  being  utilized  in  the  release 
reaction. To answer this question, 0.3 ml platelets were incubated with 20 ill of 
the ~-globulin fraction of anti-C9 for 15 min at 37°C. After this period the tube 
was transferred to the platelet aggregometer and 0.1 U of thrombin was added, 
followed by 10 t~l each of C3, C5, C6, and C7. It was found that the enhancement 
of aggregation and release initiated by C3-C7 was totally abolished by incuba- MARGARET  J.  POLLEY  AND  RALPH  NACHMAN  1719 
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Fro.  3.  Platelet  aggregometer tracing ofthrombin-mediated platelet aggregation:  (a) 0.3 
ml washed platelets in the presence of 10 i~l of aluminum hydroxide-absorbed serum; {b) 0.1 
U thrombin-0.3 ml washed platelets.  Arrow indicates addition of thrombin. 
TABLE  II 
Comparison  of Thrombin-Induced Release of l~C-Serotonin in 
the Presence and Absence of Complement 
Units ofthrombin*  AIIOH~3 absorbed se-  Release of ~*C-serotonin 
rum-~ 
0.025  -  0 
0.05  -  26 
0.1  -  59 
0.025  +  28 
0.05  +  64 
0.1  +  65 
* Added to 0.3 ml of washed platelets. 
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FIG.  4.  Effect of various reagents on thrombin-induced release of platelet  serotonin. Th, 
thrombin; A1.S,  fresh human serum absorbed with aluminum hydroxide;  A1.S.K.,  fresh 
human serum absorbed with aluminum hydroxide then treated with potassium thiocyanate 
(see text).  1 and 2 indicate sequence of addition. 
tion of the platelets with anti-C9.  When anti-C9 was replaced by anti-human 
serum  albumin,  there  was  no  effect on  subsequent  platelet  reactivity.  The 
enhancement  of aggregation  of release  by  C8  and  C9  alone  was  similarly 
inhibited by antisera to either C3 or to C5 (Fig. 6). 
Thus C3,  C5,  C6, C7, C8, and C9,  when mixed together in the absence of any 
known activating components of the classic or alternative mechanism, produced 
an  enhancement of thrombin-induced aggregation  and  release  equivalent to 
that induced by Al(OH).~ serum. 
Mechanism  of Activation  of Complement  by  Thrombin.  The  observation 
that  addition  of C3,  C5,  C6,  C7,  C8,  and  C9  in  the  absence  of any  known 
activator of complement led  to  enhanced  thrombin-induced  aggregation  and 
release of serotonin, suggested the possibility that complement was activated 
by  a  method distinct  from the  known  classic  or alternative mechanisms.  To 
clarify this possibility, serum reagents were utilized in which a key component 
of either system was absent. The serum totally deficient in C2 was utilized as a 
serum in which the classic mechanism was inhibited. As shown in Fig. 7, when 
this  serum  was  absorbed  in  the  usual  way  with  aluminum  hydroxide and 
utilized as a  source of complement, thrombin-induced release of serotonin was MARGARET  J.  POLLEY  AND  RALPH  NACHMAN 
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equal  to  that  obtained  with  C2-sufficient  normal  serum.  A  blockage  of the 
alternative  mechanism  was  produced  by  heat  inactivation  (50°C,  30  min)  of 
Factor B.  Aluminum hydroxide-absorbed heated serum  was indistinguishable 
from  unheated serum  in  mediating release  of serotonin.  Further,  blockage  of 
both the classic  and alternative mechanisms was produced by heating at 50°C 
for  30  min  the  C2-deficient  serum  that  had  been  absorbed  with  aluminum 
hydroxide. This serum reagent was also indistinguishable from normal serum 1722  COMPLEMENT  AND  PLATELET  FUNCTION 
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Fro.  7.  Effect  of various  reagents  on  thrombin-induced  release  of platelet  serotonin.  C2 
def, serum from patient deficient  in C2 absorbed with aluminum  hydroxide.  C2 def50°C30 ', 
serum  from  patient  deficient  in  C2  absorbed  with  aluminum  hydroxide,  then  heated  at 
50°C for 30 min.  Other abbreviations  are the same as in the legend to Fig.  4. 
in  inducing  enhancement  of thrombin-induced  release  of serotonin.  Platelet 
aggregation in each experiment corresponded to serotonin release. 
To ascertain whether platelet-bound C2 or Factor B were contributing to the 
release reaction in the absence of exogenous C2 or Factor B, experiments were 
performed in which the  platelets  were reacted  with antibody  to either C2  or 
Factor  B  before  they  were  exposed  to  C2-deficient  serum,  Factor  B-depleted 
serum,  or C2-deficient  serum that  had been  heated.  Neither antibody  caused 
any decrease in the platelet aggregation or release of serotonin. 
DFP  Treatment  of Thrombin.  Treatment  of thrombin  with  DFP  totally 
inhibited its ability to aggregate platelets and to release serotonin both in the 
presence and absence of complement. 
Discussion 
In a previous communication (6), we demonstrated the presence of ultrastruc- 
tural lesions on the surface of platelets that had been incubated with thrombin 
and complement. We showed that these morphologic membrane perturbations 
were dependent on the presence of thrombin and C3.  In the present study we 
have extended these studies and demonstrated cellular uptake of C3 and C5 by 
the  platelets  and  have  investigated  the  role  of  complement  in  thrombin- 
mediated platelet functions. 
Utilizing radioactively labeled C3 and C5,  we were able to demonstrate both 
C3 and C5 on the platelet surface. The uptake of C3 was very much less than 
the  uptake  seen  when  complement  was  activated  on  the  platelet  surface  by 
either  the  classic  mechanism  or  the  alternative  mechanism.  However,  the 
uptake of C5 was similar to that produced by activation of the classic mecha- 
nism.  That the platelet membrane was an integral component of this reaction 
was demonstrated by the finding that a similar activation of complement and MARGARET  J.  POLLEY  AND  RALPH  NACHMAN  1723 
uptake of C3 and C5 was not seen when the platelets were replaced with either 
erythrocytes or leukocytes. 
The  uptake  and  spatial  organization of these components were  visualized 
utilizing  ferritin  conjugated  to  anti-C3  or  anti-C5  and  electron  microscopy. 
Whereas the uptake of ferritin conjugated to anti-C5 was similar to that found 
when  complement  was  activated  by  the  classic  mechanism,  the  uptake  of 
ferritin  conjugated  to  anti-C3  was  totally  different  from  that  seen  when 
complement was activated by either the classic or the alternative mechanism. 
When complement was activated by the antibody-mediated classic mechanism, 
the distribution of the C3 ferritin marker was similar to that published (24) for 
its distribution on erythrocytes. However, after thrombin-mediated complement 
activity, there were very few molecules of C3 per cell. In fact, the number of C3 
molecules approximated the number of C5  molecules, whereas when comple- 
ment was activated by the classic mechanism, a  10-fold greater number of C3 
molecules was obtained than of C5 molecules, and by the alternative mechanism 
a  20-fold  difference was  seen.  When  the  molecules  were  visualized  on  the 
platelet surface utilizing a ferritin marker, it was found that large areas of the 
platelet membrane had no C3  and the  C3  that was present was focalized in 
large clusters visualized as 20-30 ferritin molecules. 
Zimmerman and Kolb (4) have reported uptake of C3 and the C5-C9 complex 
when platelets are incubated in serum.  However, it is not clear whether the 
mechanism of uptake is the same as that demonstrated in the present study. 
The results of our studies led  us  to  investigate the  role of complement in 
thrombin-mediated  platelet  function.  Initially  in  these  studies  we  utilized 
aluminum hydroxide-absorbed serum  as  a  source  of complement.  With  this 
reagent we found increased platelet aggregation and release of serotonin in the 
presence of complement. That the release of serotonin was a  nonlytic process 
was demonstrated by the finding that no lactic dehydrogenase was liberated 
during  this  reaction.  A  role  for  complement  in  thrombin-mediated platelet 
function has been previously suggested (5). These authors demonstrated that 
retraction and lysis of thrombin-induced blood clots were found to be inhibited 
by monospecific antisera to C3 and C4. Also thrombin was shown to cleave C3 
into C3a-like and C3b-like peptides. However, the C3a produced by cleavage of 
C3 with thrombin had no anaphylatoxin activity (14). 
The use of purified components of complement in place of aluminum hydrox- 
ide-absorbed serum  as  a  source of complement demonstrated that  maximum 
thrombin-induced platelet aggregation and release could be  achieved by the 
addition of C3, C5, C6, C7, C8, and C9 in the absence of any previously described 
C3 convertase. Further, the sequence of addition of thrombin and complement 
was important. Considerably more serotonin was released when thrombin was 
added before the components of complement than when the components were 
added  before  the  thrombin.  All  six  components  were  required  for  maximal 
aggregation and release.  However, C3,  C5,  C6,  and C7 induced a considerable 
enhancement over that obtained with thrombin in the absence of complement. 
The  release  induced  by  C3-C7  was  facilitated  by  platelet-bound  C9  (and 
probably C8) as demonstrated by the fact that the C3-C7 reactivity was inhibited 
if the platelets were first treated with anti-C9 (Fig. 6).  Some enhancement of 
release was obtained when C8 and C9 alone were added. That this release was 1724  COMPLEMENT  AND  PLATELET  FUNCTION 
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due to the presence of platelet-bound C3 and C5 was evidenced by the finding 
that it was inhibited by anti-C3 and anti-C5. 
Thus the data suggest that thrombin and the platelet membrane generate a 
C3 convertase that is distinct from those previously described as a consequence 
of the activation of the classic or alternative mechanism. Because the sequence 
of addition of thrombin and C3-C9 is important, it appears that if thrombin is 
allowed first to interact with the platelet (presumably the thrombin-receptor; 
25-27),  this  interaction brings  the  activation of the  C3-C9  onto the  platelet 
surface in contrast to the reaction taking place in the fluid phase. It will be of 
some interest in the future to determine whether the membrane attack complex 
(C5b-C9)  is  assembled on  the platelet surface as  a  consequence of thrombin 
action. 
Confirmatory data for lack of activation of either the classic mechanism or 
the alternative mechanism were obtained in experiments in which C2-deficient 
or Factor B-depleted serum was used. These sera, used as a  source of comple- 
ment, induced enhancement of thrombin-mediated aggregation and release of 
serotonin which was indistinguishable from that obtained with normal serum. 
Cell-bound C2 or Factor B was not responsible for this reactivity because prior 
treatment of the platelets with the corresponding antibody had no effect on the 
reactivity of the sera.  We suggest, as illustrated in Fig. 8,  that there exists a 
third  mechanism  leading  to  the  activation  of complement.  This  pathway 
requires thrombin and the platelet membrane and enters the known comple- 
ment sequence at the C3 stage. It will be of great interest to determine whether 
other platelet membrane perturbants, such as collagen or ADP,  have similar 
properties.  Complement is not essential for thrombin-mediated platelet func- 
tion; however, considerable enhancement of its reactivity can be obtained by 
the addition of C3, C5, C6, C7, C8, and C9. 
Summary 
Thrombin-mediated platelet  membrane-specific  uptake  of C3  and  C5  was 
demonstrated by radiolabeled components and was visualized electron micro- 
scopically utilizing a  ferritin marker conjugated to  monospecific antibody to 
each component. The role of complement in thrombin-induced platelet function 
was determined. Though complement was not essential for thrombin-induced 
platelet aggregation and release of serotonin, these activities were significantly MARGARET  J.  POLLEY  AND  RALPH  NACHMAN  1725 
increased if complement was present. The release of serotonin was found to be a 
nonlytic process because Under the conditions employed, no lactic dehydrogen- 
ase was released.  The activation of complement was induced  by a  mechanism 
which has not been previotisly described. Thrombin associated with the platelet 
membrane presumably formed a  C3 convertase that entered the known comple- 
ment sequence  at the  C3 stage  and  proceeded to activate the terminal  compo- 
nents through the known sequence to C9. 
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